AstraZeneca, Merck’s Lynparza meets primary goal in late-stage study

AstraZeneca (AZN -1.1%) and Merck (MRK +1.5%) report PROfound Phase 3 clinical trial results showed statistically significant and clinically meaningful improvement with Lynparza (olaparib) in the primary endpoint of radiographic progression-free survival (rPFS) in certain tumors reducing the risk of disease progression or death by a median of 7.4 months vs. 3.6 months for those receiving abiraterone or enzalutamide; LYNPARZA reduced the risk of disease progression or death by 66% for these men.

Trial also met key secondary endpoint of rPFS in overall HRRm population. where Lynparza reduced the risk of disease progression or death by 51% and improved rPFS to a median of 5.8 months vs. 3.5 months for those receiving abirateron or enzalutamide.

Secondary endpoint of median time to pain progression was not reached.

Trial showed a confirmed overall response rate, a key secondary endpoint of 33.3% for Lynparza vs. 2.3% for abiratone or enzalutammide in patients with BRCA1/2 or ATM mutations.

Safety and tolerability profile of Lynparza in the PROfound trial was in line with that observed in prior clinical trials.

Previously: AstraZeneca and Merck’s Lynparza shows positive effect in late-stage ovarian cancer study (Aug. 14)

https://seekingalpha.com/news/3502632-astrazeneca-mercks-lynparza-meets-primary-goal-late-stage-study